Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two ...

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential ...

Investor AB maintains low leverage, with a net debt of ~SEK 9.5 billion and a conservative long-term approach. Read why I ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

Harvey Jones says the GSK share price has dramatically underperformed FTSE 100 rival AstraZeneca, which has had a stellar run ...

AstraZeneca’s share price has fallen a long way this year, which could mean a bargain to be had, so I ran the key numbers to check if this is the case. The post AstraZeneca’s share price is down 20% ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.